On Dec. 15, 2021, Novavax announced the submission of a New Drug Application to the Ministry of Health, Labour and Welfare in Japan for its COVID-19 vaccine by its partner Takeda Pharmaceutical.

Novavax’ recombinant nanoparticle COVID-19 vaccine with Matrix-Mﾙ adjuvant, known as TAK-019 in Japan and NVX-CoV2373 outside Japan, was the first protein-based COVID-19 vaccine to be submitted under an NDA in Japan.